Catholic mental health professionals have welcomed the federal governmentʼs move toward potential approval of psychedelic drugs for clinical treatments, describing it as a hopeful response to the nation’s growing mental health crisis while urging caution.
President Donald Trump signed an executive order in April directing federal agencies to accelerate research, regulatory review, and limited patient access to psychedelic drugs as potential treatments for serious mental illnesses, including depression, PTSD, and other treatment-resistant conditions.
Titled “Accelerating Medical Treatments for Serious Mental Illness,” the executive order defines serious mental illness as “having a diagnosable mental, behavioral, or emotional disorder that substantially interferes with a person’s life and ability to function.”
“Despite massive federal investment into researching potential advancements in mental health care and treatment, our medical research system has yet to produce approved therapies that promote enduring improvements in the mental health condition” of the most complex patients, the order says.
“Innovative methods are needed to find long-term solutions for these Americans beyond existing prescription medications.”
The order promotes research into psychedelics such as ibogaine, a naturally occurring psychoactive alkaloid derived primarily from the root bark of an African shrub. It has shown promise in treating opioid addiction (by reducing withdrawal and
